Amgen v Sanofi and Regeneron: Broad antibody patents held invalid for lack of enablement in US Lack of enablement: A conclusion of lack of enablement means that the disclosure provided in the patent specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full… Read more »
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Read more about our policy here.